Opthea: Funding, Investors & Team (Sep 2026)
Opthea Limited, previously known as Circadian Technologies, is an Australian biotechnology company that is publicly traded and focuses on creating innovative biologic treatments for eye conditions. The company's main product, OPT-302, targets VEGF-C and VEGF-D, proteins that stimulate abnormal blood vessel growth and leakage in the eyes, common features of diseases like wet AMD.
Opthea has raised $342M across 3 funding rounds on record, the most recent an undisclosed round of $114M announced in Jun 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Opthea Company Profile and Key Stats
Latest funding round on record: Jun 2024.
Opthea Funding Rounds
Opthea raised $170M in a Post-IPO Debt announced in Aug 2022.
1 years later, an undisclosed round of $57.7M was announced in Aug 2023.
10 months later, an undisclosed round of $114M was announced in Jun 2024.
Opthea Founders and Leadership Team
Contact details for the Opthea team: 1 of 1 has an email address on file.
Start 14-day free trial →Opthea Funding Compared to Other Biotechnology Startups
Opthea's latest round of $114M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Opthea in Biotechnology and South Yarra
Companies Similar to Opthea
AdvanCell is a company that focuses on developing innovative cancer treatments using alpha-emitting isotopes…
The objective of Fluent is to seamlessly integrate humans with AI, improving interaction and communication…
Mesoblast is a developer of biologic products for the broad field of regenerative medicine. Mesoblast's…
Microba Life Sciences Ltd. provides consumers, doctors, and researchers with gut microbiome testing services…
Algenie was founded on a simple realization: algae has the potential to save the earth, but only if it is…
Paradigm Pharmaceuticals is a global biopharmaceutical company driven to discover, develop, and deliver…
Imugene is a publicly-listed biotechnology company with operations in America and Europe,
BiomeBank’s mission is to treat and prevent disease by restoring gut microbial ecology
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing…
Cauldron Ferm is a technique that speeds up the production of precision fermented prototypes to commercial…
HydGene Renewables is developing a biotechnology platform that produces on-site green hydrogen from waste…
Swan Genomics is focused on commercialising an innovative new approach to DNA sequencing to deliver more…
Opthea Funding FAQs
What does Opthea do?
Opthea Limited, previously known as Circadian Technologies, is an Australian biotechnology company that is publicly traded and focuses on creating innovative biologic treatments for eye conditions. The company's main product, OPT-302, targets VEGF-C and VEGF-D, proteins that stimulate abnormal blood vessel growth and leakage in the eyes, common features of diseases like wet AMD.
How much funding has Opthea raised?
Opthea has raised $342M across 3 rounds on record. The most recent is an undisclosed round of $114M announced in Jun 2024.
When did Opthea last raise funding?
Opthea's most recent funding round on record is an undisclosed round of $114M, announced in Jun 2024.
Who is the CEO of Opthea?
Megan Baldwin is listed as CEO at Opthea.
Where is Opthea headquartered?
Opthea is based in South Yarra, Victoria, Australia.
How many employees does Opthea have?
Opthea is in the 11-50 employee band.
How does Opthea's funding compare to other Biotechnology startups?
Opthea's latest round of $114M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Opthea Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Opthea is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.